Pulse Biosciences Financial Ratios
NASDAQ: PLSEHealthcareMedical Instruments & SuppliesUSD
53.81+3.83 (+7.66%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pulse Biosciences ratio analysis
Pulse Biosciences earned a net margin of -20794.6% in FY 2025. Gross margin was -54.0% compared with a median of -822.5% over the prior 2 years. Return on equity reached -90.2%, meaning Pulse Biosciences generated -0.90 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Pulse Biosciences financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 2,578.35 | — | — | 134.29 | 292.06 | — | — | — | — | — |
| Price / book | 11.19 | 9.98 | 13.72 | — | 9.34 | 24.23 | 9.52 | 3.21 | 7.57 | 2.83 |
| Gross margin | -54.0% | — | — | -1,606.3% | -38.8% | — | — | — | — | — |
| Operating margin | -21,982.6% | — | — | -8,293.9% | -4,443.9% | — | — | — | — | — |
| Net margin | -20,794.6% | — | — | -8,357.9% | -4,489.4% | — | — | — | — | — |
| Free cash flow margin | -15,553.4% | — | — | -6,773.4% | -3,845.8% | — | — | — | — | — |
| Return on equity (ROE) | -90.2% | -46.7% | -95.2% | — | -143.5% | -217.7% | -152.8% | -56.6% | -55.6% | -37.6% |
| Return on assets (ROA) | -77.0% | -40.5% | -71.4% | -75.1% | -107.6% | -120.7% | -112.1% | -53.1% | -51.3% | -36.2% |
| Debt / equity | — | — | 0.00 | — | — | — | — | — | — | — |
| Current ratio | 10.53 | 11.88 | 6.76 | 10.39 | 6.76 | 2.95 | 5.92 | 19.42 | 17.39 | 16.40 |
| Revenue growth | — | — | -100.0% | -50.6% | — | — | — | — | — | — |